Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results

Qiagen (NYSE:QGEN) issued its quarterly earnings results on Wednesday. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01, Zacks reports. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. Qiagen updated its Q1 2025 guidance to 0.500- EPS and its FY 2025 guidance to 2.280- EPS.

Qiagen Stock Down 3.8 %

Shares of QGEN traded down $1.68 during trading hours on Thursday, reaching $42.13. The company’s stock had a trading volume of 192,178 shares, compared to its average volume of 1,118,260. The firm has a market cap of $9.35 billion, a price-to-earnings ratio of 104.98, a P/E/G ratio of 3.10 and a beta of 0.36. The company has a 50 day moving average of $43.80 and a two-hundred day moving average of $43.26. Qiagen has a 1-year low of $40.15 and a 1-year high of $49.30. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. Jefferies Financial Group restated a “buy” rating and set a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley restated an “equal weight” rating and set a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective on the stock. in a report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $50.07.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.